Landiolol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Landiolol
Landiolol.png
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C25H39N3O8
Molar mass 509.59 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Landiolol (INN) is a drug which acts as a highly cardioselective, ultra short-acting beta blocker. It is used as an antiarrhythmic agent.

Mode of action[edit]

The drug acts as an ultra-short-acting β1-selective blocking agent. It is rapidly hydrolyzed to an inactive form by both carboxylesterase in the liver and pseudocholinesterase[disambiguation needed] in the plasma, resulting in an elimination half-life of about 4 minutes. [1]

Preparation[edit]

The drug was developed by modifying the chemical structure of esmolol to produce a compound with a higher rate of cardioselectivity and a greater potency without increasing its duration of action. It is sold as landiolol hydrochloride. [1]

References[edit]

  1. ^ a b Yamamoto, Natsuko; et al. (2017). "Heart Rate Response to Intravenous Landiolol during Propofol Anesthesia". CIRCULATION CONTROL. 38 (1): 35–39. ISSN 0389-1844. doi:10.11312/ccm.38.35. Retrieved May 10, 2017. 
  • Yoshiya I (December 1998). "[Landiolol hydrochloride, a new sympathetic beta blocker]". Masui (in Japanese). 47 Suppl: S126–32. PMID 9921175. 
  • Ogata J, Okamoto T, Minami K (2003). "Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation". Can J Anaesth. 50 (7): 753. PMID 12944459. doi:10.1007/BF03018726.